| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Bankruptcy > What to Consider when Filing for Personal Bankruptcy |
|
Just Other Articles - What to Consider when Filing for Personal Bankruptcy
President Bush in April signed into law The Bankruptcy Abuse and Consumer Protection Act. This bill pro According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product mises many changes to law, and will make it more difficult for the average person in financial trouble ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in to have debts removed with bankruptcy. Recent social and economic changes indicate that those consider lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ing a bankruptcy should do so now, as the queue is getting longer. It will be now be harder to file un here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe er Chapter 7 of the code, which allows the courts to wave consumer debt and give the debtor a new start d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro . Filings posted will be tested and those who have a decent income it seems will have to file under a m ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ore strenuous Chapter 13, which demands repayment by installments and the assistance of a lawyer. Now l easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ooming, bankruptcy filings are not only higher than they were previously, but are also higher than expe nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ted. Acros the country, filings are substantially higher than last year, and some bankruptcy practition and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ers say that their business has increased dramatically. To make it more confusing is another law, tha ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi t requires credit card companies to establish a payment schedule that permits consumers to repay debts ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a in amended installments. Since early year, most credit card providers have doubled their minimum paymen dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod s. An average person with say $12,000 in credit card debt, will have approximate monthly payment increa cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ses from between $150 to $450, an increase most people can ill afford. This increase in bankruptcy fil tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ings has overwhelmed bankruptcy lawyers, who face a burden of being liable for false information filed t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel by clients once the new law takes effect. Certainly an unwelcome change. This additional liability, to ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ether with the additional tasks, has prompted many lawyers to raise fees subsstantally over the same ti y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products me as last year. What does this mean for bad debt? From here on, bankruptcy filings will be more conf . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de using, complicated and costly. The system is already overloaded with bankruptcy cases. If you suspect y elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ou're in the bankruptcy category, you should move on it now. Waiting even another day could be too late tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:The Dangerous Consequences of Micromanaging Your Business The Squeeze Page and Opt In Email Lists
|